Blackstone Group Inc Makes New $6.05 Million Investment in HUTCHISON CHINA/S (NASDAQ:HCM)
Blackstone Group Inc bought a new position in shares of HUTCHISON CHINA/S (NASDAQ:HCM) during the 2nd quarter, Holdings Channel.com reports. The fund bought 275,000 shares of the company’s stock, valued at approximately $6,050,000.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Aperio Group LLC acquired a new position in HUTCHISON CHINA/S during the 2nd quarter worth approximately $50,000. Quantamental Technologies LLC increased its position in HUTCHISON CHINA/S by 607.9% during the 2nd quarter. Quantamental Technologies LLC now owns 2,782 shares of the company’s stock worth $61,000 after purchasing an additional 2,389 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of HUTCHISON CHINA/S in the 2nd quarter worth approximately $91,000. Tower Research Capital LLC TRC grew its holdings in shares of HUTCHISON CHINA/S by 1,454.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,787 shares of the company’s stock worth $106,000 after acquiring an additional 4,479 shares during the period. Finally, Pinebridge Investments L.P. acquired a new stake in shares of HUTCHISON CHINA/S in the 2nd quarter worth approximately $110,000. Institutional investors own 26.50% of the company’s stock.
A number of equities research analysts recently weighed in on HCM shares. Macquarie started coverage on HUTCHISON CHINA/S in a report on Friday, July 5th. They issued an “outperform” rating on the stock. BidaskClub upgraded HUTCHISON CHINA/S from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Zacks Investment Research upgraded HUTCHISON CHINA/S from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Wednesday, July 10th. Finally, ValuEngine upgraded HUTCHISON CHINA/S from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $25.41.
About HUTCHISON CHINA/S
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China and Hong Kong. The company operates through Innovation Platform and Commercial Platform segments.
See Also: Why is the price-sales ratio important?
Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).
Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.